Prudential Financial’s Enanta Pharmaceuticals ENTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$480K Sell
37,995
-2,020
-5% -$27.1K ﹤0.01% 1879
2025
Q4
$631K Buy
+40,015
New +$508K ﹤0.01% 1759
2025
Q1
Sell
-60,364
Closed -$347K 2317
2024
Q4
$347K Sell
60,364
-96,700
-62% -$927K ﹤0.01% 1952
2024
Q3
$1.63M Hold
157,064
﹤0.01% 1606
2024
Q2
$2.04M Sell
157,064
-15,200
-9% -$205K ﹤0.01% 1424
2024
Q1
$3.01M Sell
172,264
-21,300
-11% -$282K ﹤0.01% 1213
2023
Q4
$1.82M Buy
193,564
+13,500
+7% +$126K ﹤0.01% 1493
2023
Q3
$2.01M Buy
180,064
+147,812
+458% +$2.38M ﹤0.01% 1366
2023
Q2
$690K Sell
32,252
-10,747
-25% -$317K ﹤0.01% 1985
2023
Q1
$1.74M Buy
42,999
+23,250
+118% +$1.11M ﹤0.01% 1431
2022
Q4
$919K Hold
19,749
﹤0.01% 1749
2022
Q3
$1.02M Buy
19,749
+860
+5% +$50.2K ﹤0.01% 1741
2022
Q2
$893K Sell
18,889
-405
-2% -$22K ﹤0.01% 1850
2022
Q1
$1.37M Buy
19,294
+139
+0.7% +$9.04K ﹤0.01% 1728
2021
Q4
$1.43M Sell
19,155
-255
-1% -$20K ﹤0.01% 1702
2021
Q3
$1.1M Sell
19,410
-130
-0.7% -$6.43K ﹤0.01% 1755
2021
Q2
$860K Sell
19,540
-1,006
-5% -$49.3K ﹤0.01% 1902
2021
Q1
$1.01M Sell
20,546
-363
-2% -$18.1K ﹤0.01% 1822
2020
Q4
$880K Sell
20,909
-2,640
-11% -$116K ﹤0.01% 1813
2020
Q3
$1.08M Buy
23,549
+2,247
+11% +$109K ﹤0.01% 1608
2020
Q2
$1.07M Sell
21,302
-4,264
-17% -$221K ﹤0.01% 1613
2020
Q1
$1.31M Sell
25,566
-50,141
-66% -$2.67M ﹤0.01% 1566
2019
Q4
$4.68M Buy
75,707
+42,377
+127% +$2.63M 0.01% 1162
2019
Q3
$2M Sell
33,330
-334
-1% -$24.8K ﹤0.01% 1581
2019
Q2
$2.84M Buy
33,664
+650
+2% +$58.5K ﹤0.01% 1424
2019
Q1
$3.15M Sell
33,014
-6,215
-16% -$558K 0.01% 1352
2018
Q4
$2.78M Sell
39,229
-180,586
-82% -$13.8M ﹤0.01% 1357
2018
Q3
$18.8M Sell
219,815
-82,772
-27% -$8.29M 0.03% 638
2018
Q2
$35.1M Buy
302,587
+85,397
+39% +$8.52M 0.05% 419
2018
Q1
$17.6M Buy
217,190
+124,458
+134% +$9.58M 0.03% 665
2017
Q4
$5.44M Buy
92,732
+46,135
+99% +$2.31M 0.01% 1111
2017
Q3
$2.18M Buy
46,597
+490
+1% +$19.7K ﹤0.01% 1547
2017
Q2
$1.66M Sell
46,107
-23,564
-34% -$754K ﹤0.01% 1651
2017
Q1
$2.15M Buy
69,671
+20,743
+42% +$646K ﹤0.01% 1535
2016
Q4
$1.64M Sell
48,928
-32,476
-40% -$931K ﹤0.01% 1635
2016
Q3
$2.17M Buy
81,404
+34,330
+73% +$797K ﹤0.01% 1470
2016
Q2
$1.04M Sell
47,074
-1,640
-3% -$42.9K ﹤0.01% 1818
2016
Q1
$1.43M Buy
48,714
+18,344
+60% +$511K ﹤0.01% 1689
2015
Q4
$1M Buy
30,370
+600
+2% +$19.6K ﹤0.01% 1784
2015
Q3
$1.08M Sell
29,770
-15,200
-34% -$653K ﹤0.01% 1725
2015
Q2
$2.02M Buy
+44,970
New +$1.75M ﹤0.01% 1569
2014
Q4
Sell
-14,970
Closed -$592K 2205
2014
Q3
$592K Buy
+14,970
New +$597K ﹤0.01% 1877
2014
Q1
Sell
-15,070
Closed -$411K 2268
2013
Q4
$411K Buy
+15,070
New +$365K ﹤0.01% 2009

Other funds holding ENTA

Prudential Financial's ENTA Position: Q1 2026 in Review

Prudential Financial reduced its Enanta Pharmaceuticals (ENTA) stake by 5% in Q1 2026, selling an estimated $27.1K and leaving 37,995 shares worth $480K. The position accounts for ﹤0.01% of the portfolio, ranked #1879.

Prudential Financial first reported a position in ENTA in Q4 2013 and has held it in 43 quarters since. The position peaked at $35.1M in Q2 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Prudential Financial held 37,995 shares of Enanta Pharmaceuticals worth $480K as of Q1 2026.
  • Prudential Financial sold 2,020 Enanta Pharmaceuticals shares in Q1 2026, an estimated $27.1K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #1879 holding.
  • Prudential Financial first reported a position in Enanta Pharmaceuticals in Q4 2013 and has held it in 43 quarters since.
  • Prudential Financial's Enanta Pharmaceuticals position peaked at $35.1M in Q2 2018.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.